S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
If you're happy with stocks yielding you 4% or 5% a year, you don't need this. But if you want to see how we built a portfolio that now pays us a 67% cash on cash return - with no leverage, options, or gimmicks.

NASDAQ:CNCR - Loncar Cancer Immunotherapy ETF Stock Price, Forecast & News

-0.14 (-0.59 %)
(As of 01/20/2020 04:00 PM ET)
Today's Range
Now: $23.43
50-Day Range
MA: $23.63
52-Week Range
Now: $23.43
Volume4,411 shs
Average Volume15,050 shs
Market Capitalization$38.67 million
P/E RatioN/A
Dividend Yield0.00%

Basic Details

Issuer Exchange Traded Concepts
Fund NameLoncar Cancer Immunotherapy ETF
Tax ClassificationRegulated Investment Company
Inception Date10/13/2015
Fund ManagerDenise M. Krisko

Fund Focus

Asset ClassEquity
BenchmarkLoncar Cancer Immunotherapy Index
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$38.23 million
Average Daily Volume$13,681.70

ETF Expenses

Management Fee0.79%
Other Expenses0.00%
Total Expenses0.79%
Fee Waiver0.00%
Net Expenses0.79%

Administrator, Advisor and Custodian

AdministratorU.S. Bancorp Fund Services, LLC
AdvisorExchange Traded Concepts, LLC
CustodianU.S. Bank National Association
DistributorQuasar Distributors, LLC
Transfer AgentU.S. Bancorp Fund Services, LLC
Lead Market MakerJane Street

Receive CNCR News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCR and its competitors with MarketBeat's FREE daily newsletter.

Geographic Exposure of Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR)
Currency Exposure of Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR)
Sector Exposure of Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR)
Industry Exposure of Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR)


Investors looking for the best way to potentially double their money in 2020 -- regardless of whether the overall markets are up or down -- should look no further than these 3 unique stocks.

This Special Report reveals the names of these stocks and provides everything you need to invest right away.

Loncar Cancer Immunotherapy ETF (NASDAQ:CNCR) Frequently Asked Questions

What is Loncar Cancer Immunotherapy ETF's stock symbol?

Loncar Cancer Immunotherapy ETF trades on the NASDAQ under the ticker symbol "CNCR."

Has Loncar Cancer Immunotherapy ETF been receiving favorable news coverage?

News coverage about CNCR stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Loncar Cancer Immunotherapy ETF earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Loncar Cancer Immunotherapy ETF.

What other stocks do shareholders of Loncar Cancer Immunotherapy ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Loncar Cancer Immunotherapy ETF investors own include Tesla (TSLA), Netflix (NFLX), Atlassian (TEAM), Cannabix Technologies (BLO), IDEXX Laboratories (IDXX), Momo (MOMO), Paypal (PYPL), Alibaba Group (BABA), Square (SQ) and Etsy (ETSY).

Who are Loncar Cancer Immunotherapy ETF's major shareholders?

Loncar Cancer Immunotherapy ETF's stock is owned by a number of of retail and institutional investors. Top institutional investors include Simon Quick Advisors LLC (0.09%).

Which major investors are buying Loncar Cancer Immunotherapy ETF stock?

CNCR stock was bought by a variety of institutional investors in the last quarter, including Simon Quick Advisors LLC.

How do I buy shares of Loncar Cancer Immunotherapy ETF?

Shares of CNCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Loncar Cancer Immunotherapy ETF's stock price today?

One share of CNCR stock can currently be purchased for approximately $23.43.

How big of a company is Loncar Cancer Immunotherapy ETF?

Loncar Cancer Immunotherapy ETF has a market capitalization of $38.67 million. View Additional Information About Loncar Cancer Immunotherapy ETF.

MarketBeat Community Rating for Loncar Cancer Immunotherapy ETF (NASDAQ CNCR)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  78 (Vote Underperform)
Total Votes:  125
MarketBeat's community ratings are surveys of what our community members think about Loncar Cancer Immunotherapy ETF and other stocks. Vote "Outperform" if you believe CNCR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Featured Article: Percentage Decliners

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel